Literature DB >> 15850403

Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling.

Maoqing Dong1, Guangming Liu, Delia I Pinon, Laurence J Miller.   

Abstract

Type A and B cholecystokinin (CCK) receptors are highly homologous members of the class-I family of G protein-coupled receptors that bind CCK with high affinity. However, they have divergent structural specificities, with the type A receptor requiring seven carboxyl-terminal residues including a sulfated tyrosine and the type B receptor requiring only the carboxyl-terminal tetrapeptide. The aim of this work was to utilize affinity labeling to determine spatial approximations with photolabile p-benzoyl-l-phenylalanine (Bpa) residues sited at each end of CCK as docked at the type B CCK receptor, contrasting this with analogous work using similar probes docked at the type A receptor. Both probes were fully efficacious, potent agonists that stimulated intracellular calcium in receptor-bearing CHO-CCKBR cells (EC(50) values: Bpa(24) probe, 41 +/- 9 pM; Bpa(33) probe, 15 +/- 3.3 pM). They bound specifically, with high affinity (K(i) values: Bpa(24) probe, 0.60 +/- 0.17 nM; Bpa(33) probe, 0.58 +/- 0.11 nM). Cyanogen bromide cleavage of the covalently labeled receptor suggested the first extracellular loop as the region of labeling by each probe, distinct from the type A CCK receptor regions labeled using the same probes (third loop and amino-terminal tail, respectively). This was confirmed by subsequent enzymatic and chemical cleavage of labeled wild-type and mutant receptors. Sequential cycles of Edman degradation of labeled receptor fragments identified the specific residues within loop one labeled by each probe (Bpa(24) probe labeled Phe(122); Bpa(33) probe labeled Thr(119)). This provides a direct demonstration of distinct modes of docking the same high-affinity ligand to highly homologous receptors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15850403     DOI: 10.1021/bi050130q

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

1.  Differential sensitivity of types 1 and 2 cholecystokinin receptors to membrane cholesterol.

Authors:  Ross M Potter; Kaleeckal G Harikumar; S Vincent Wu; Laurence J Miller
Journal:  J Lipid Res       Date:  2011-10-21       Impact factor: 5.922

2.  Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding.

Authors:  Maoqing Dong; Ashton M Vattelana; Polo C-H Lam; Andrew J Orry; Ruben Abagyan; Arthur Christopoulos; Patrick M Sexton; David R Haines; Laurence J Miller
Journal:  Mol Pharmacol       Date:  2014-10-15       Impact factor: 4.436

3.  Elimination of a cholecystokinin receptor agonist 'trigger' in an effort to develop positive allosteric modulators without intrinsic agonist activity.

Authors:  Aditya J Desai; Brad R Henke; Laurence J Miller
Journal:  Bioorg Med Chem Lett       Date:  2015-03-24       Impact factor: 2.823

4.  Molecular basis for binding and subtype selectivity of 1,4-benzodiazepine antagonist ligands of the cholecystokinin receptor.

Authors:  Erin E Cawston; Polo C H Lam; Kaleeckal G Harikumar; Maoqing Dong; Alicja M Ball; Mary Lou Augustine; Eyup Akgün; Philip S Portoghese; Andrew Orry; Ruben Abagyan; Patrick M Sexton; Laurence J Miller
Journal:  J Biol Chem       Date:  2012-03-30       Impact factor: 5.157

5.  Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.

Authors:  Aditya J Desai; Polo C H Lam; Andrew Orry; Ruben Abagyan; Arthur Christopoulos; Patrick M Sexton; Laurence J Miller
Journal:  J Med Chem       Date:  2015-12-10       Impact factor: 7.446

6.  Direct demonstration of unique mode of natural peptide binding to the type 2 cholecystokinin receptor using photoaffinity labeling.

Authors:  Maoqing Dong; Laurence J Miller
Journal:  Peptides       Date:  2013-06-14       Impact factor: 3.750

7.  A type 1 cholecystokinin receptor mutant that mimics the dysfunction observed for wild type receptor in a high cholesterol environment.

Authors:  Aditya J Desai; Kaleeckal G Harikumar; Laurence J Miller
Journal:  J Biol Chem       Date:  2014-05-13       Impact factor: 5.157

Review 8.  Structural basis of cholecystokinin receptor binding and regulation.

Authors:  Laurence J Miller; Fan Gao
Journal:  Pharmacol Ther       Date:  2008-05-11       Impact factor: 12.310

Review 9.  Roles of Cholecystokinin in the Nutritional Continuum. Physiology and Potential Therapeutics.

Authors:  Laurence J Miller; Kaleeckal G Harikumar; Denise Wootten; Patrick M Sexton
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-02       Impact factor: 5.555

10.  Sensitivity of cholecystokinin receptors to membrane cholesterol content.

Authors:  Aditya J Desai; Laurence J Miller
Journal:  Front Endocrinol (Lausanne)       Date:  2012-10-18       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.